Klingenstein Fields & Co’s Novo Nordisk NVO Stock Holding History

Klingenstein Fields & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$361K	Hold	9,820	–	–	0.01%	144
2025 Q4	$500K	Sell	9,820 -100	-1%	-$5.11K	0.02%	121
2025 Q3	$550K	Sell	9,920 -35	-0.4%	-$2.05K	0.02%	121
2025 Q2	$687K	Sell	9,955 -280	-3%	-$19K	0.03%	110
2025 Q1	$711K	Sell	10,235 -369	-3%	-$30.5K	0.03%	108
2024 Q4	$912K	Hold	10,604	–	–	0.04%	99
2024 Q3	$1.26M	Sell	10,604 -116	-1%	-$15.5K	0.05%	89
2024 Q2	$1.53M	Hold	10,720	–	–	0.06%	85
2024 Q1	$1.38M	Sell	10,720 -166	-2%	-$19.8K	0.06%	90
2023 Q4	$1.13M	Hold	10,886	–	–	0.05%	91
2023 Q3	$990K	Sell	10,886 -120	-1%	-$10.6K	0.05%	91
2023 Q2	$891K	Sell	11,006 -24	-0.2%	-$1.96K	0.04%	96
2023 Q1	$878K	Sell	11,030 -200	-2%	-$14.2K	0.04%	96
2022 Q4	$760K	Sell	11,230 -20	-0.2%	-$1.17K	0.04%	104
2022 Q3	$560K	Sell	11,250 -60	-0.5%	-$3.21K	0.03%	109
2022 Q2	$630K	Sell	11,310 -220	-2%	-$12.2K	0.03%	113
2022 Q1	$640K	Sell	11,530 -300	-3%	-$15.4K	0.03%	120
2021 Q4	$662K	Sell	11,830 -170	-1%	-$9.21K	0.03%	123
2021 Q3	$576K	Sell	12,000 -200	-2%	-$9.67K	0.02%	131
2021 Q2	$511K	Sell	12,200 -340	-3%	-$13.2K	0.02%	138
2021 Q1	$423K	Sell	12,540 -566	-4%	-$20.2K	0.02%	141
2020 Q4	$458K	Hold	13,106	–	–	0.02%	138
2020 Q3	$455K	Sell	13,106 -74	-0.6%	-$2.47K	0.02%	135
2020 Q2	$432K	Sell	13,180 -110	-0.8%	-$3.51K	0.02%	132
2020 Q1	$400K	Sell	13,290 -2,380	-15%	-$70.9K	0.03%	132
2019 Q4	$453K	Sell	15,670 -450	-3%	-$12.5K	0.02%	137
2019 Q3	$417K	Sell	16,120 -1,290	-7%	-$32.6K	0.02%	145
2019 Q2	$444K	Sell	17,410 -400	-2%	-$9.89K	0.02%	144
2019 Q1	$466K	Sell	17,810 -910	-5%	-$22.4K	0.03%	141
2018 Q4	$431K	Hold	18,720	–	–	0.02%	149
2018 Q3	$441K	Hold	18,720	–	–	0.02%	160
2018 Q2	$432K	Sell	18,720 -130	-0.7%	-$3.09K	0.02%	163
2018 Q1	$464K	Sell	18,850 -130	-0.7%	-$3.41K	0.02%	156
2017 Q4	$509K	Sell	18,980 -270	-1%	-$6.87K	0.02%	158
2017 Q3	$463K	Sell	19,250 -500	-3%	-$11.3K	0.02%	158
2017 Q2	$424K	Hold	19,750	–	–	0.02%	162
2017 Q1	$339K	Sell	19,750 -5,500	-22%	-$95.8K	0.01%	169
2016 Q4	$453K	Hold	25,250	–	–	0.02%	160
2016 Q3	$525K	Hold	25,250	–	–	0.02%	144
2016 Q2	$679K	Hold	25,250	–	–	0.03%	133
2016 Q1	$684K	Sell	25,250 -100	-0.4%	-$2.68K	0.03%	135
2015 Q4	$736K	Hold	25,350	–	–	0.04%	129
2015 Q3	$687K	Sell	25,350 -1,400	-5%	-$39.6K	0.03%	134
2015 Q2	$732K	Hold	26,750	–	–	0.03%	135
2015 Q1	$714K	Hold	26,750	–	–	0.03%	140
2014 Q4	$566K	Hold	26,750	–	–	0.03%	146
2014 Q3	$637K	Hold	26,750	–	–	0.03%	141
2014 Q2	$618K	Sell	26,750 -400	-1%	-$8.83K	0.03%	152
2014 Q1	$620K	Sell	27,150 -330	-1%	-$7.03K	0.03%	153
2013 Q4	$508K	Hold	27,480	–	–	0.02%	205
2013 Q3	$465K	Sell	27,480 -1,300	-5%	-$21.9K	0.02%	209
2013 Q2	$446K	Buy	+28,780	New	+$479K	0.02%	223

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Klingenstein Fields & Co's NVO Position: Q1 2026 in Review

Klingenstein Fields & Co held its Novo Nordisk (NVO) position steady in Q1 2026 at 9,820 shares worth $361K. The position accounts for 0.01% of the portfolio, ranked #144.

Klingenstein Fields & Co first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.53M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Klingenstein Fields & Co held 9,820 shares of Novo Nordisk worth $361K as of Q1 2026.
Klingenstein Fields & Co left its Novo Nordisk share count unchanged in Q1 2026.
Novo Nordisk made up 0.01% of Klingenstein Fields & Co's portfolio in Q1 2026, its #144 holding.
Klingenstein Fields & Co first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
Klingenstein Fields & Co's Novo Nordisk position peaked at $1.53M in Q2 2024.
1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Klingenstein Fields & Co's 13F filing for Q1 2026, filed 13 May 2026.